FiercePharmaOriginal article
{"a":[{"_":"Boehringer Ingelheim offloads Shanghai CDMO to local antibody developer","$":{"href":"/pharma/boehringer-ingelheim-offloads-shanghai-cdmo-local-antibody-developer","hreflang":"en"}}]}
lead antibody drug candidateNeutral
AI Analysis
Summary
Boehringer Ingelheim divests its Shanghai biologics contract manufacturing facility to Chinese antibody developer Raas Blood Products, providing the latter with an established production base for its lead antibody candidate.
Outcome Details
Boehringer Ingelheim divests Shanghai biologics CDMO unit to Raas Blood Products
Importance:4/10
Sentiment:
0.00
M&ACDMObiologicsChinamanufacturing
Related Companies
Read the original article
Published by FiercePharma on September 24, 2026 11:10 AM